Literature DB >> 28674121

Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

Jonathan D Wasserman1, Gail E Tomlinson2, Harriet Druker3, Junne Kamihara4, Wendy K Kohlmann5, Christian P Kratz6, Katherine L Nathanson7, Kristian W Pajtler8,9, Andreu Parareda10, Surya P Rednam11, Lisa J States12, Anita Villani3, Michael F Walsh13, Kristin Zelley14, Joshua D Schiffman15.   

Abstract

Children and adolescents who present with neuroendocrine tumors are at extremely high likelihood of having an underlying germline predisposition for the multiple endocrine neoplasia (MEN) syndromes, including MEN1, MEN2A and MEN2B, MEN4, and hyperparathyroid-jaw tumor (HPT-JT) syndromes. Each of these autosomal dominant syndromes results from a specific germline mutation in unique genes: MEN1 is due to pathogenic MEN1 variants (11q13), MEN2A and MEN2B are due to pathogenic RET variants (10q11.21), MEN4 is due to pathogenic CDKN1B variants (12p13.1), and the HPT-JT syndrome is due to pathogenic CDC73 variants (1q25). Although each of these genetic syndromes share the presence of neuroendocrine tumors, each syndrome has a slightly different tumor spectrum with specific surveillance recommendations based upon tumor penetrance, including the age and location for which specific tumor types most commonly present. Although the recommended surveillance strategies for each syndrome contain similar approaches, important differences do exist among them. Therefore, it is important for caregivers of children and adolescents with these syndromes to become familiar with the unique diagnostic criteria for each syndrome, and also to be aware of the specific tumor screening and prophylactic surgery recommendations for each syndrome. Clin Cancer Res; 23(13); e123-e32. ©2017 AACRSee all articles in the online-only CCR Pediatric Oncology Series. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28674121      PMCID: PMC5547889          DOI: 10.1158/1078-0432.CCR-17-0548

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  100 in total

1.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

Review 2.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

3.  High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients.

Authors:  Tsuneo Imai; Shinya Uchino; Takahiro Okamoto; Shinichi Suzuki; Shinji Kosugi; Toyone Kikumori; Akihiro Sakurai
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

4.  Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype.

Authors:  Donatella Malanga; Silvia De Gisi; Miriam Riccardi; Marianna Scrima; Carmela De Marco; Mercedes Robledo; Giuseppe Viglietto
Journal:  Eur J Endocrinol       Date:  2011-11-30       Impact factor: 6.664

Review 5.  Genetic mutations in sporadic pituitary adenomas--what to screen for?

Authors:  Anne-Lise Lecoq; Peter Kamenický; Anne Guiochon-Mantel; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2014-10-28       Impact factor: 43.330

6.  Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1.

Authors:  Behnam Asgharian; Maria L Turner; Fathia Gibril; Laurence K Entsuah; Jose Serrano; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

7.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.

Authors:  Anita Villani; Ari Shore; Jonathan D Wasserman; Derek Stephens; Raymond H Kim; Harriet Druker; Bailey Gallinger; Anne Naumer; Wendy Kohlmann; Ana Novokmet; Uri Tabori; Marta Tijerin; Mary-Louise C Greer; Jonathan L Finlay; Joshua D Schiffman; David Malkin
Journal:  Lancet Oncol       Date:  2016-08-05       Impact factor: 41.316

Review 8.  Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance.

Authors:  Matthew J Glascock; Sally E Carty
Journal:  Surg Oncol       Date:  2002-11       Impact factor: 3.279

9.  Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.

Authors:  Maurizio Iacobone; Giulia Masi; Luisa Barzon; Andrea Porzionato; Veronica Macchi; Francesco Antonio Ciarleglio; Giorgio Palù; Raffaele De Caro; Giovanni Viel; Gennaro Favia
Journal:  Langenbecks Arch Surg       Date:  2009-06-16       Impact factor: 3.445

Review 10.  MENX and MEN4.

Authors:  Natalia S Pellegata
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

View more
  8 in total

Review 1.  Pediatric hyperparathyroidism: review and imaging update.

Authors:  Hedieh Khalatbari; Safia H E Cheeney; Scott C Manning; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2021-04-27

Review 2.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 3.  Imaging surveillance for children with predisposition to renal tumors.

Authors:  Abhay S Srinivasan; Sandra Saade-Lemus; Sabah E Servaes; Michael R Acord; Janet R Reid; Sudha A Anupindi; Lisa J States
Journal:  Pediatr Radiol       Date:  2019-10-16

4.  Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.

Authors:  Anthony J Gill; Grace Lim; Veronica K Y Cheung; Juliana Andrici; Joanna L Perry-Keene; Julie Paik; Loretta Sioson; Adele Clarkson; Amy Sheen; Catherine Luxford; Marianne S Elston; Goswin Y Meyer-Rochow; M Teresa Nano; Schelto Kruijff; Anton F Engelsman; Mark Sywak; Stanley B Sidhu; Leigh W Delbridge; Bruce G Robinson; Deborah J Marsh; Christopher W Toon; Angela Chou; Roderick J Clifton-Bligh
Journal:  Am J Surg Pathol       Date:  2019-01       Impact factor: 6.394

5.  Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.

Authors:  Tadashi Kumamoto; Fumito Yamazaki; Yoshiko Nakano; Chieko Tamura; Shimon Tashiro; Hiroyoshi Hattori; Akira Nakagawara; Yukiko Tsunematsu
Journal:  Int J Clin Oncol       Date:  2021-10-11       Impact factor: 3.402

Review 6.  Diagnostic Strategies and Algorithms for Investigating Cancer Predisposition Syndromes in Children Presenting with Malignancy.

Authors:  Linda Rossini; Caterina Durante; Silvia Bresolin; Enrico Opocher; Antonio Marzollo; Alessandra Biffi
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

7.  The Usefulness of Maximum Standardized Uptake Value at the Delayed Phase of Tc-99m sestamibi single-photon emission computed tomography/computed tomography for Identification of Parathyroid Adenoma and Hyperplasia.

Authors:  Hoon Young Suh; Hee Young Na; So Yeon Park; June Young Choi; Young So; Won Woo Lee
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

8.  Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant.

Authors:  Kate E Lines; Lisa B Nachtigall; Laura E Dichtel; Treena Cranston; Hannah Boon; Xun Zhang; Kreepa G Kooblall; Mark Stevenson; Rajesh V Thakker
Journal:  J Endocr Soc       Date:  2020-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.